Articles
Follow our developments and deepen your industry knowledge by following our updates and news.
Antibody-Drug Conjugates (ADCs): Revolutionizing Cancer Treatment
Antibody-drug conjugates (ADCs) represent a groundbreaking advancement in oncology, combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs. This approach aims to maximize efficacy while minimizing toxicity, offering a promising future for cancer treatment. By targeting specific antigens on cancer cells, ADCs can deliver powerful cytotoxic agents directly to the tumor, reducing the adverse effects typically associated with conventional chemotherapy.
Targeted Cancer Therapy
ADCs are primarily used to treat various cancers, including solid tumors and blood cancers. They target specific antigens on cancer cells, allowing for precise delivery of the cytotoxic drug to the tumor site. This targeted approach not only enhances the efficacy of the treatment but also minimizes damage to healthy tissues, leading to better patient outcomes. The ability to tailor ADCs to different cancer types by selecting appropriate antibodies and payloads makes them a versatile tool in oncology.
Booming Market Trends
The ADC market is experiencing robust growth,driven by an increasing number of clinical trials and market deals, as well as approved molecules expansion. The market size is expanding rapidly, with significant investments in ADC research and development. According to recent reports, the global ADC market was valued at approximately USD 7,7 billion in 2023 and is projected to grow up to 27,8 bn USD by 20321.
.webp)
As of May 2025, seventeen ADCs have received global approval, two of them approved in 2025, showcasing exceptional clinical effectiveness in treating both solid tumors and blood cancers. Additionally, ADCs are the fastest-growing group in oncology trials with 857 ADC clinical trials2 initiated in the past decade. The ADC market is also characterized by a high level of research and development activity. ADCs are a driver of deals in oncology, with 80% of value share3. They are also anticipated to continue playing a significant role in the oncology dealmaking landscape, according to IQVIA Pharma Deals, proving keen interest in the segment.
The payloads used in both approved and ADCs in development, can be generally classified into three main categories: microtubule inhibitors, topoisomerase I (Topo-1) inhibitors, and DNA-damaging agents. Looking at ADC pipeline, microtubule inhibitors are the most promising group, representing 41% of the clinical-stage research4. The majority of ADC assets are aimed at solid tumor indications, with 80% of ADC trials concentrating on solid cancers5.The impressive clinical and commercial achievements of ADCs make them a highly attractive investment opportunity for both major and emerging players on the pharmaceutical market.
Mechanism of Action
ADCs consist of three main components:
Monoclonal Antibody (MAB)
a specialized protein engineered to precisely target and bind to cancer cells. It is the guiding component, enabling the ADC to selectively attach to cancer cells
Cytotoxic Drug (Payload)
the active pharmaceutical ingredient responsible for the therapeutic effect, which involves damaging or killing cancer cells. The selection of the payload is critical as it directly influences the treatment's efficacy and safety.
Chemical Linker
compound that connects the monoclonal antibody to the cytotoxic or therapeutic drug payload. The linker ensures the stability of the ADC, facilitating the proper delivery and release of the drug to the targeted cells.
The antibody targets specific antigens on cancer cells, the linker releases the cytotoxic drug inside the cell, leading to cancer cell death while minimizing the impact on healthy tissues. The mechanism of action of ADCs involves several key steps:
This targeted delivery mechanism allows ADCs to achieve high concentrations of the cytotoxic drug within the tumor while sparing healthy tissues, thereby reducing systemic toxicity.
The Power of HP APIs
Highly Potent Active Pharmaceutical Ingredients (HP APIs) are crucial for the efficacy of ADCs. They enhance the therapeutic index and precision targeting of ADCs, making them more effective in treating cancer. HP APIs are characterized by their ability to exert therapeutic effects at very low doses. This high potency allows for the delivery of powerful cytotoxic agents directly to cancer cells, increasing the likelihood of tumor eradication while minimizing off-target effects.
The development and manufacturing of HP APIs require specialized facilities and expertise due to their toxicity. These facilities must adhere to stringent safety and containment measures to protect workers and prevent cross-contamination.
.png)
Read more about Polpharma HP API capabilities
HP APIs used in ADCs include a variety of cytotoxic agents, such as microtubule inhibitors (e.g., auristatins and maytansinoids), DNA-damaging agents (e.g., calicheamicins), and topoisomerase inhibitors (e.g., SN-38). These agents are selected based on their ability to induce cancer cell death while minimizing harm to healthy tissues.
Future Prospects
Next-generation ADCs will prioritize innovations in antibody targets, payloads, and linker chemistry to achieve a balance between potency and manageable side effects. ADCs have proven to be valuable, targeted therapies with the potential to replace traditional, non-specific chemotherapy. Future advancements in ADCs are expected to extend their use to earlier lines of therapy and earlier stages of disease.
ADCs, along with bi-/multi-specific antibodies and radioligand therapies, are becoming significant market segments projected to generate substantial annual global sales. In the past five years, these modalities have grown much faster than the overall oncology market. Looking forward, they are anticipated to continue outperforming the overall oncology market, with a combined 5-year CAGR of approximately 20%, reaching total sales of $37 billion by 20286.
Despite the high levels of clinical andcommercial uncertainty, the ADC market is set for significant growth, driven by the ongoing success of marketed blockbusters and the development of new-generation ADCs with enhanced specificity and cytotoxicity.
Cornerstone of future oncology therapies
ADCs offer hope for more effective and safer cancer therapies. Continued research and development will enhance their capabilities, making them play a pivotal role in the future of oncology. The ability to combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs positions ADCs as a promising therapeutic option for various cancers.
SOURCES:
1 - Breaking New Ground: Advancing Cancer Care with Novel Therapeutic Modalities. Deep dive: Antibody drug conjugates, bi-/multi-specifics and radioligand therapies; IQVIA
2 -Global Oncology Trends 2024, OUTLOOK TO 2028; MAY 2024; IQVIA
3 - Antibody Drug Conjugates Market (7th Edition), 2023-2035; Roots Analysis
4 - Surge in ADC Deals Drives Oncology Dealmaking; IQVIA Pharma Deals — September 2024; IQVIA
.webp)
%20(1).webp)
